Making and breaking tolerance

Current Opinion in Immunology

Volumn 14, Issue 6, 2002, Pages 744-759

  Ohashi, Pamela S ^a   DeFranco, Anthony L ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CELL SURFACE RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; PROTEIN KINASE C; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; DROSOPHILA PROTEIN; LYN PROTEIN-TYROSINE KINASE; MEMBRANE PROTEIN; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE;

ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; AUTOREGULATION; CELL MATURATION; CELL SURVIVAL; CROSS REACTION; DENDRITIC CELL; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; MEDIATOR; NONHUMAN; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; ANIMAL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; HOMEOSTASIS; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; DENDRITIC CELLS; DROSOPHILA PROTEINS; HOMEOSTASIS; IMMUNE TOLERANCE; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 0036888669     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00406-5     Document Type: Review

References (168)

1. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 19:2001;47-64.
2. Steinman R.M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 191:2000;411-416.
3. Kurts C., Sutherland R.M., Davey G., Li M., Lew A.M., Blanas E., Carbone F.R., Miller J.F.A.P., Heath W.R. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA. 96:1999;12703-12707.
4. Morgan D.J., Kreuwel H.T.C., Sherman L.A. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol. 163:1999;723-727.
5. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 3:2002;135-142.
6. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., Lederman S., Colonna M., Cortesini R., Dalla-Favera R., Suciu-Foca N. Tolerization of dendritic cells by Ts cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol. 3:2002;237-243.
7. Homann D., Jahreis A., Wolfe T., Hughes A., Coon B., van Stipdonk M.J.B., Prilliman K.R., Schoenberger S.P., von Herrath M.G. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK-DC regulatory cells. Immunity. 16:2002;403-415.
8. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med. 195:2002;F9-F14.
9. Bendelac A., Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med. 195:2002;F19-F23.
10. Dresser D.W. Effectiveness of lipid and lipidophilic substances as adjuvants. Nature. 191:1961;1169-1171.
11. Brooke M.S. Conversion of immunological paralysis to immunity by endotoxin. Nature. 206:1965;635-636.
12. Chiller J.M., Weigle W.O. Termination of tolerance to human gamma globulin in mice by antigen and bacterial lipopolysaccharide (endotoxin). J Exp Med. 137:1973;740-750.
13. Ohashi P.S., Oehen S., Bürki K., Pircher H., Ohashi C.T., Odermatt B., Malissen B., Zinkernagel R., Hengartner H. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 65:1991;305-317.
14. Röcken M., Urban J.F., Shevach E.M. Infection breaks T-cell tolerance. Nature. 359:1992;79-82.
15. Matzinger P. The danger model: a renewed sense of self. Science. 296:2002;301-305.
16. Medzhitov R., Janeway C.A. Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 296:2002;298-300.
17. + T cells. Nat Immunol. 2:2001;1010-1017.
18. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., Nussenzweig M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 194:2001;769-779.
19. Diehl L., den Boer A., Schoenberger S., van der Voort E.I.H., Schumacher T.N.M., Melief C.J.M., Offringa R., Toes R.E.M. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med. 5:1999;774-779.
20. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 5:1999;780-787.
21. Garza K.M., Chan S.M., Suri R., Nguyen L.T., Odermatt B., Schoenberger S.P., Ohashi P.S. Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med. 191:2000;2021-2027.
22. Bansal-Pakala P., Jember A.G.H., Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med. 7:2001;907-912. The authors demonstrated that stimulating OX40 expressed on CD4 cells can reverse the induction of anergy. This is the first study to demonstrate the ability of OX40 to influence tolerance.
23. Janeway C.A. Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 20:2002;197-216.
24. Fallon P.G., Allen R.L., Rich T. Primitive toll signalling: bugs, flies, worms and man. Trends Immunol. 22:2001;63-66.
25. O'Neill L.A.J. Toll-like receptor signal transduction and the tailoring of innate immunity: a role for Mal. Trends Immunol. 23:2002;296-300.
26. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., Kitamura T., Kosugi A., Kimoto M., Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 3:2002;667-672.
27. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2:2001;675-680.
28. Kawai T., Adachi O., Ogawa T., Takeda K., Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 11:1999;115-122.
29. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., Jefferies C.A., Mansell A.S., Brady G., Brint E., Dunne A., Gray P., Harte M.T., et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. 413:2001;78-83.
30. Horng T., Barton G.M., Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol. 2:2001;835-841.
31. Kobayashi K., Inohara N., Hernandez L.D., Galá J.E., Núñez G., Janeway C.A., Medzhitov R., Flavell R.A. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature. 416:2002;194-199.
32. Suzuki N., Suzuki S., Duncan G.S., Millar D.G., Wada T., Mirtsos C., Takada H., Wakeham A., Itie A., Li S., et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature. 416:2002;750-756.
33. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A. Jr, Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 110:2002;191-202.
34. Bouchon A., Facchetti F., Weigand M.A., Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 410:2001;1103-1107. Bouchon et al. have examined the role of TREM-1 - a new receptor of the immunoglobulin superfamily that is expressed on neutrophils and monocytes. Upregulation of this receptor is associated with bacterial infections in humans, and studies show that TREM-1 is an amplifier of microbial induced inflammatory responses.
35. Chung D.-H., Seaman W.E., Daws M.R. Characterization of TREM-3, an activating receptor on mouse macrophages: definition of a family of single Ig domain receptors on mouse chromosome 17. Eur J Immunol. 32:2002;59-66.
36. Vella A.T., McCormack J.E., Linsley P.S., Kappler J.W., Marrack P. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity. 2:1995;261-270.
37. + T cells to cause immunopathology. J Exp Med. 187:1998;763-774.
38. Reis e Sousa C., Germain R.N. Analysis of adjuvant function by direct visualization of antigen presentation in vivo: Endotoxin promotes accumulation of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue. J Immunol. 162:1999;6552-6561.
39. Kadowaki N., Ho S., Antonenko S., de Waal Malefyt R., Kastelein R.A., Bazan F., Liu Y.-J. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med. 194:2001;863-869. This is a key paper showing that different subsets of DCs preferentially express certain TLRs.
40. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., Giese T., Engelmann H., Endres S., Krieg A.M., Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 31:2001;3026-3037.
41. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature. 413:2001;732-738.
42. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., Eng J.K., Akira S., Underhill D.M., Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 410:2001;1099-1103.
43. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 3:2002;196-200.
44. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Hermann W., Lipford G., Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 3:2002;499.
45. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
46. Häcker H., Vabulas R.M., Takeuchi O., Hoshino K., Akira S., Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated fractor (TRAF)6. J Exp Med. 192:2002;595-600.
47. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M., Klinman D.M. Cutting Edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol. 167:2001;3555-3558.
48. Park Y., Lee S.W., Sung Y.C. Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3′-OH kinase pathway. J Immunol. 168:2002;5-8. The authors demonstrate that CpG motifs play an important role in regulating DC survival via PI3K-induced upregulation of cIAP1 and cIAP2.
49. Blachere N.E., Li Z., Chandawarkar R.Y., Suto R., Jaikaria N.S., Basu S., Udono H., Srivastava P.K. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med. 186:1997;1315-1322.
50. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2:2002;185-194.
51. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 5:1999;1249-1255.
52. Chen W., Syldath U., Bellmann K., Burkart V., Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol. 162:1999;3212-3219.
53. Basu S., Binder R.J., Suto R., Anderson K.M., Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int Immunol. 12:2000;1539-1546.
54. Singh-Jasuja H., Scherer H.U., Hilf N., Arnold-Schild D., Rammensee H.-G., Toes R.E.M., Schild H. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol. 30:2000;2211-2215.
55. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 191:2000;423-433.
56. Lehner T., Bergmeier L.A., Wang Y., Tao L., Sing M., Spallek R., Van der Zee R. Heat shock proteins generate β-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol. 30:2000;594-603.
57. Somersan S., Larsson M., Fonteneau J.F., Basu S., Srivastava P., Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol. 167:2001;4844-4852.
58. Moré S.H., Breloer M., von Bonin A. Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells. Int Immunol. 13:2001;1121-1127.
59. Kuppner M.C., Gastpar R., Gelwer S., Nössner E., Ochmann O., Scharner A., Issels R.D. The role of heat shock protein (hsp70) in dendritic cell maturation: Hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol. 31:2001;1602-1609.
60. Breloer M., Dorner B., Moré S.H., Roderian T., Fleischer B., von Bonin A. Heat shock proteins as 'danger signals': eukaryotic Hsp60 enhances and accelerates antigen-specific IFN-γ production in T cells. Eur J Immunol. 31:2001;2051-2059.
61. Beere H.M., Green D.R. Stress management-heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol. 11:2001;6-10.
62. Randow F., Seed B. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat Cell Biol. 3:2001;891-896. Mutants of the murine pre-B cell line 70Z/3 were generated that are resistant to LPS stimulation. They demonstrated that gp96 interacts with TLR1, TLR2 and TLR4, and is essential for surface expression.
63. Wallin R.P.A., Lundqvist A., Moré S.H., von Bonin A., Kiessling R., Ljunggren H.-G. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23:2002;130-135.
64. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 14:2001;303-313.
65. Berwin B., Hart J.P., Pizzo S.V., Nicchitta C.V. Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. J Immunol. 168:2002;4282-4286.
66. Asea A., Kraeft S.-K., Kurt-Jones E.A., Stevenson M.A., Chen L.B., Finberg R.W., Koo G.C., Calderwood S.K. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 6:2000;435-442.
67. Ohashi K., Burkart V., Flohé S., Kolb H. Cutting Edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol. 164:2000;561.
68. Kol A., Lichtman A.H., Finberg R.W., Libby P., Kurt-Jones E.A. Cutting Edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol. 164:2000;13-17.
69. Vabulas R.M., Ahmad-Nejad P., da Costa C., Miethke T., Kirschning C.J., Häcker H., Wagner H. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem. 276:2001;31332-31339.
70. Vabulas R.M., Ahmad-Nejad P., Ghose S., Kirschning C.J., Issels R.D., Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor. J Biol Chem. 277:2002;15107-15112.
71. Asea A., Rehli M., Kabingu E., Boch J.A., Baré O., Auron P.E., Stevenson M.A., Calderwood S.K. Novel signal transduction pathway utilized by extracellular HSP70. J Biol Chem. 277:2002;15028-15034.
72. Lipsker D., Ziyian U., Spehner D., Proamer F., Bausinger H., Jeannin P., Salamero J., Bohbot A., Cazenave J.-P., Drillien R., et al. Heat shock proteins 70 and 60 share common receptors which are expressed on human monocyte-derived but not epidermal dendritic cells. Eur J Immunol. 32:2002;322-332.
73. Habich C., Baumgart K., Kolb H., Burkart V. The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J Immunol. 168:2002;569-576.
74. Wang Y., Kelly C.G., Karttunen J.T., Whittall T., Lehner P.J., Duncan L., MacAry P., Younson J.S., Singh M., Oehlmann W., et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity. 15:2001;971-983.
75. Li M., Carpio D.F., Zheng Y., Bruzzo P., Singh V., Ouaaz F., Medzhitov R.M., Beg A.A. An essential role of the NF-κB/toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol. 166:2001;7128-7135. This paper demonstrates that necrotic cells trigger NF-κB via TLR2 or the TLR2:TLR6 heterodimer, and that necrotic cells induce KC and MIP-2 secretion, but they do not influence IL-12 production.
76. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:2002;191-195. The authors demonstrate the significance of HMGB1, a molecule that is released by necrotic cells but not apoptotic cells, which promotes inflammation.
77. Termeer C.C., Hennies J., Voith U., Ahrens T., Weiss J.M., Prehm P., Simon J.C. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol. 165:2000;1863-1870.
78. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., Miyake K., Freudenberg M., Galanos C., Simon J.C. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor. J Exp Med. 195:2002;99-111.
79. Kodaira Y., Nair S.K., Wrenshall L.E., Gilboa E., Platt J.L. Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. J Immunol. 165:2000;1599-1604.
80. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., Chow J.C., Strauss J.F. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 276:2001;10229-10233.
81. Lu Q., Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 293:2001;306-311. This is the first study that identifies the importance of the Tyro 3 family of tyrosine kinases in regulating lymphoid homeostasis and autoimmunity.
82. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med. 195:2002;1289-1302.
83. - dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 192:2000;1685-1695.
84. Kurts C., Cannarile M., Klebba I., Brocker T. Cutting Edge: dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J Immunol. 166:2001;1439-1442. In this study, transgenic mice were made expressing β2-microglobulin on DCs using the CD11c promoter. The CD11c-β2-microglobulin transgene was bred onto a β2-microglobulin-deficient background. Using bone marrow chimeras (donor CD11c-β2min) made with mice expressing the RIP-ova transgene, the authors could demonstrate that the reconstituted expression of class I molecules on DCs was sufficient to promote cross presentation and tolerance in vivo.
85. Hugues S., Mougneau E., Ferlin W., Jeske D., Hofman P., Homann D., Beaudoin L., Schrike C., von Herrath M., Lehuen A., Glaichenhaus N. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic β cells. Immunity. 16:2002;169-181. This paper demonstrates that apoptosis and cross presentation can lead to the induction of regulatory T cells that can prevent adoptively transferred autoimmune diabetes in NOD mice.
86. Zhang Y., O'Brien B., Trudeau J., Tan R., Santamaria P., Dutz J.P. In situ β cell death promotes priming of diabetogenic CD8 T lymphocytes. J Immunol. 168:2002;1466-1472. A clear demonstration that β cell death is detected by self-reactive T cells in vivo.
87. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., Speiser D., Ohashi P.S. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med. 195:2002;423-435. This paper provides evidence that tumours can break ignorance and tolerance.
88. Goodnow C.C. Balancing immunity and tolerance: Deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA. 93:1996;2264-2271.
89. Nemazee D. Receptor selection in B and T lymphocytes. Annu Rev Immunol. 18:2000;19-51.
90. Cooke M.P., Heath A.W., Shokat K.M., Zeng Y., Finkelman F.D., Linsley P.S., Howard M., Goodnow C.C. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med. 179:1994;425-438.
91. Eris J.M., Basten A., Brink R., Doherty K., Kehry M.R., Hodgkin P.D. Anergic self-reactive B cells present self antigen and respond normally to CD40- dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc Natl Acad Sci USA. 91:1994;4392-4396.
92. Benschop R.J., Aviszus K., Zhang X., Manser T., Cambier J.C., Wysocki L.J. Activation and anergy in bone marrow B cells of a novel immunoglobulin transgenic mouse that is both hapten specific and autoreactive. Immunity. 14:2001;33-43.
93. Vilen B.J., Burke K.M., Sleater M., Cambier J.C. Transmodulation of BCR signaling by transduction-incompetent antigen receptors: implications for impaired signaling in anergic B cells. J Immunol. 168:2002;4344-4351.
94. Rathmell J.C., Cooke M.P., Ho W.Y., Grein J., Townsend S.E., Davis M.M. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature. 376:1995;181-184.
95. Rathmell J.C., Townsend S.E., Xu J.C., Flavell R.A., Goodnow C.C. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)- ligands modulated by the B cell antigen receptor. Cell. 87:1996;319-329.
96. Rothstein T.L., Wang J.K., Panka D.J., Foote L.C., Wang Z., Stanger B., Cui H., Ju S.T., Marshak-Rothstein A. Protection against Fas-dependant Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature. 374:1995;163-165.
97. Sekiguchi D.R., Jainandunsing S.M., Fields M.L., Maldonado M.A., Madaio M.P., Erikson J., Weigert M., Eisenberg R.A. Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell tolerance in anti-double-stranded DNA B cells. J Immunol. 168:2002;4142-4153. B cell tolerance to dsDNA was abrogated when T cell help was provided to anergic B cells by using alloreactive T cells.
98. Seo S.J., Fields M.L., Buckler J.L., Reed A.J., Mandik-Nayak L., Nish S.A., Noelle R.J., Turka L.A., Finkelman F.D., Caton A.J., Erikson J. The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity. 16:2002;535-546. Anergic anti-dsDNA B cells were induced to produce autoantibodies by the provision of T cell help directed against an antigen expressed in the B cell via a transgene. In addition, regulatory T cells were capable of inhibiting the response.
99. Foote L.C., Marshak-Rothstein A., Rothstein T.L. Tolerant B lymphocytes acquire resistance to Fas-mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded. J Exp Med. 187:1998;847-853.
100. Mandik-Nayak L., Seo S.-J., Eaton-Bassiri A., Allman D., Hardy R.R., Erikson J. Functional consequences of the developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J Immunol. 164:2000;1161-1168.
101. Chu Y.P., Taylor D., Yan H.G., Diamond B., Spatz L. Persistence of partially functional double-stranded (ds) DNA binding B cells in mice transgenic for the IgM heavy chain of an anti-dsDNA antibody. Int Immunol. 14:2002;45-54.
102. Ray S.K., Putterman C., Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci USA. 93:1996;2019-2024.
103. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Schlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 416:2002;603-607. B cells capable of making rheumatoid factor autoantibodies were stimulated in vitro by addition of anti-chromatin antibodies. Activation of the B cells occurred via a MyD88-dependent signalling pathway and had other properties suggesting it may involve a TLR, perhaps TLR9. These studies suggest that innate immune receptors may play a key role in the breakdown of B cell tolerance in systemic autoimmunity.
104. Shlomchik M.J., Craft J.E., Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 1:2001;147-153.
105. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 20:2002;709-760.
106. Wakeland E.K., Liu K., Graham R.R., Behrens T.W. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 15:2001;397-408.
107. Morel L., Blenman K.R., Croker B.P., Wakeland E.K. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci USA. 98:2001;1787-1792. Genetic dissection of the Sle1 locus indicate that it can be subdivided into four loci, each of which contributes to systemic autoimmunity. These studies illustrate the complexity of genetic susceptibility to autoimmune disease and suggest that susceptibility genes may cause relatively minor changes in processes contributing to immune tolerance or activation.
108. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity. 15:2001;775-785. Evidence is presented that Sle1c represents a partial loss of function allele of Cr2, which encodes the complement receptors CR1 and CR2 in the mouse. Although previous work has indicated that CR2 is a positive factor for B cell activation, there was also evidence it participates in induction of tolerance of B cells. The latter function could explain how a partial loss of CR2 function contributes to the development of autoimmunity.
109. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., Fearon D.T. C3d of complement as molecular adjuvant: bridging innate and acquired immunity. Science. 271:1996;348-350.
110. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot E.M., Goodnow C.C., Carroll M.C. A critical role for complement in maintenance of self-tolerance. Immunity. 9:1998;721-731.
111. Chen Z., Koralov S.B., Kelsoe G. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J Exp Med. 192:2000;1339-1352.
112. DeFranco A.L., Chan V.W., Lowell C.A. Positive and negative roles of the tyrosine kinase Lyn in B cell function. Semin Immunol. 10:1998;299-307.
113. Brauweiler A., Tamir I., Dal Port J., Benschop R.J., Helgason C.D., Humphries R.K., Freed J.H., Cambier J.C. Differential regulation of B cell development, activation, and death by the src homology 2 domain-containing 5′ inositol phosphatase (SHIP). J Exp Med. 191:2000;1545-1554.
114. Brauweiler A., Tamir I., Marschner S., Helgason C.D., Cambier J.C. Partially distinct molecular mechanisms mediate inhibitory FcγRIIB signaling in resting and activated B cells. J Immunol. 167:2001;204-211.
115. Scharenberg A.M., Kinet J.P. The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP? Cell. 87:1996;961-964.
116. Hibbs M.L., Tarlinton D.M., Armes J., Grail D., Hodgson G., Maglitto R., Stacker S.A., Dunn A.R. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 83:1995;301-311.
117. Nishizumi H., Taniuchi I., Yamanashi Y., Kitamura D., Ilic D., Mori S., Watanabe T., Yamamoto T. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity. 3:1995;549-560.
118. Chan V.W., Meng F., Soriano P., DeFranco A.L., Lowell C.A. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity. 7:1997;69-81.
119. Yu C.C., Lowell C.A., DeFranco A.L. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr Biol. 11:2001;34-38. Deficiency in Lyn is found to enhance IgG anti-dsDNA production relative to total IgG by more than 1 000-fold. Thus, although deficiency of Lyn leads to enhanced BCR signalling, it also leads to profound loss of tolerance to dsDNA.
120. O'Keefe T.L., Williams G.T., Batista F.D., Neuberger M.S. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med. 189:1999;1307-1313.
121. Cornall R.J., Cyster J.G., Hibbs M.L., Dunn A.R., Otipoby K.L., Clark E.A., Goodnow C.C. Polygenic autoimmune traits: lyn,CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity. 8:1998;497-508.
122. Du C., Sriram S. Increased severity of experimental allergic encephalomyelitis in lyn-/-mice in the absence of elevated proinflammatory cytokine response in the central nervous system. J Immunol. 168:2002;3105-3112. Deficiency in Lyn is found to lead to greater susceptibility to EAE, through increased autoantibody production.
123. Seo S.-J., Buckler J., Erikson J. Novel roles for lyn in B cell migration and lipopolysaccharide responsiveness revealed using anti-double-stranded DNA Ig transgenic mice. J Immunol. 166:2001;3710-3723.
124. Helgason C.D., Kalberer C.P., Damen J.E., Chappel S.M., Pineault N., Krystal G., Humphries R.K. A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of B lymphocytes in SHIP-/- mice. J Exp Med. 191:2000;781-794.
125. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity. 13:2000;277-285.
126. Bolland S., Yim Y.-S., Tus K., Wakeland E.K., Ravetch J.V. Genetic modifiers of systemic lupus erythematosus in Fcγ RIIB-/-mice. J Exp Med. 195:2002;1167-1174. Genetic analysis of autoimmune susceptibility in mice lacking the negative regulator of B cell activation and myeloid activity, FcγRIIB.
127. Ochi H., Watanabe T. Negative regulation of B cell receptor-mediated signaling in B-1 cells through CD5 and Ly49 co-receptors via lyn kinase activity. Int Immunol. 12:2000;1417-1423.
128. Gary-Gouy H., Harriague J., Dalloul A., Donnadieu E., Bismuth G. CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif. J Immunol. 168:2002;232-239.
129. Hippen K.L., Tze L.E., Behrens T.W. CD5 maintains tolerance in anergic B cells. J Exp Med. 191:2000;883-890.
130. Pan C., Baumgarth N., Parnes J.R. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity. 11:1999;495-506.
131. Okazaki T., Maeda A., Nishimura H., Kurosaki T., Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA. 98:2001;13866-13871.
132. Nishimura H., Nose M., Hiai H., Minator N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 11:1999;141-151.
133. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science. 291:2001;319-322. The authors present a demonstration that PD-1 deficient mice develop an autoimmune attack on cardiomyocytes that appears to be mediated by autoantibodies.
134. Nishimura H., Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 22:2001;265-268.
135. Hermiston M.L., Xu Z., Majeti R., Weiss A. Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. J Clin Invest. 109:2002;9-14.
136. Majeti R., Bilwes A.M., Noel J.P., Hunter T., Weiss A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science. 279:1998;88-91.
137. Majeti R., Xu Z., Parslow T.G., Olson J.L., Daikh D.I., Killeen N., Weiss A. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 103:2000;1059-1070.
138. Fujimoto M., Fujimoto Y., Poe J.C., Jansen P.J., Lowell C.A., DeFranco A.L., Tedder T.F. CD19 regulates Src-family protein tyrosine kinase activation in B lymphocytes via processive amplification. Immunity. 13:2000;47-57.
139. Sato S., Ono N., Steeber D.A., Pisetsky D.S., Tedder T.F. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol. 157:1996;4371-4378.
140. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 165:2000;6635-6643.
141. Inaoki M., Sato S., Weintraub B.C., Goodnow C.C., Tedder T.F. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med. 186:1997;1923-1931.
142. Rudd C.E., Schneider H. Lymphoctye signaling: Cbl sets the threshold for autoimmunity. Curr Biol. 10:2000;R344-R347.
143. Bachmaier K., Krawczyk C., Kozieradzki I., Kong Y.-Y., Sasaki T., Oliveira-dos-Santos A.J., Mariathasan S., Bouchard D., Wakeham A., Itie A., et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature. 403:2000;211-216.
144. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.-J., Jang I.K., Gutkind J.S., Shevach E., Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. Nature. 403:2000;216-220.
145. Mecklenbrauker I., Saijo K., Zheng N.Y., Leitges M., Tarakhovsky A. Protein kinase Cδ controls self-antigen-induced B-cell tolerance. Nature. 416:2002;860-865. Genetic ablation of PKCδ leads to defects in B cell anergy induction, but not in B cell activation, indicating a selective role of PKCδ in B cell tolerance induction.
146. Miyamoto A., Nakayama K., Imaki H., Hirose S., Jiang Y., Abe M., Tsukiyama T., Nagahama H., Ohno S., Hatakeyama S., Nakayama K.I. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ Nature. 416:2002;865-869. Genetic ablation of PKCδ leads to spontaneous autoimmunity, in agreement with the findings of [145••] .
147. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 190:1999;1697-1710.
148. Khare S.D., Sarosi I., Xia X.-Z., McCabe S., Miner K., Solovyev I., Hawkins N., Kelley M., Chang D., Van G., et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA. 97:2000;3370-3375.
149. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., Xu W., Parrish-Novak J., Foster D., Lofton-Day C., et al. TACl and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 404:2000;995-999.
150. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., Tschopp J., Cachero T.G., Batten M., Wheway J., et al. Association of BAFF/BlyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest. 109:2002;59-68. Overexpression of BAFF in transgenic mice leads to symptoms of the autoimmune disease Sjogren's syndrome.
151. Schneider P., Takatsuka H., Wilson A., Mackay F., Tardivel A., Lens S., Cchero T.G., Finke D., Beermann F., Tschopp J. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med. 194:2001;1691-1697.
152. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., Frew E., Scott M.L. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 293:2001;2111-2114. Genetic ablation of BAFF leads to loss of marginal zone B cells and mature follicular B cells.
153. Hsu B.L., Harless S.M., Lindsley R.C., Hilbert D.M., Cancro M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol. 168:2002;5993-5996. The effect of BAFF on the number of B cells in mice is shown to be mediated via promotion of survival of marginal zone and mature follicular B cells.
154. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., Hession C., Schneider P., Sizing I.D., Mullen C., et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 293:2001;2108-2111. Identification of a novel receptor for BAFF that is mutated in A/WySnJ mice, which have severely decreased numbers of mature B cells. See also [155••] .
155. Yan M., Brady J.R., Chan B., Lee W.P., Hsue B., Harless S., Cancro M., Grewal I.S., Dixit V.M. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 11:2001;1547-1552. Identification of a novel receptor for BAFF that is mutated in A/WySnJ mice, which have severely decreased numbers of mature B cells. See also [154••] .
156. Harless S.M., Lentz V.M., Sah A.P., Hsu B.L., Clise-Dwyer K., Hilbert D.M., Hayes C.E., Cancro M.P. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol. 11:2001;1986-1989. A demonstration that A/WySnJ B cells cannot respond to BAFF. This work demonstrates that the BAFF receptor is the key receptor mediating the in vivo survival effect of BAFF on B cells.
157. Chan T.O., Rittenhouse S.E., Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem. 68:1999;965-1014.
158. Ohashi P.S. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol. 2:2002;427-438.
159. +/- mice. Science. 285:1999;2122-2125.
160. Borlado L.R., Redondo C., Alverez B., Jimenez C., Criado L.M., Flores J., Marcos M.A., Martinez A.C., Balomenos D., Carrera A.C. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14:2000;895-903.
161. Parsons M.J., Jones R.G., Tsao M.S., Odermatt B., Ohashi P.S., Woodgett J.R. Expression of active PKB in T cells perturbs both T and B cell homeostasis and promotes inflammation. J Immunol. 167:2001;42-48.
162. Suzuki A., Yamaguchi M.T., Ohteki T., Sasaki T., Kaisho T., Kimura Y., Yoshida R., Wakeham A., Higuchi T., Fukumoto M., et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 14:2001;523-534.
163. Jones R.G., Elford A.R., Parsons M.J., Wu L., Krawczyk C.M., Yeh W.C., Hakem R., Rottapel R., Woodgett J.R., Ohashi P.S. CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med. 196:2002;335-348. This paper demonstrates that active PKB is able to impair the Fas death signalling pathway by inhibiting the recruitment of procaspase 8 to the death inducing signalling complex.
164. Dijkers P.F., Medema R.H., Lammers J.-W.J., Koenderman L., Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 10:2000;1201-1204.
165. Kip1 and bim in response to IL-2. J Immunol. 168:2002;5024-5031.
166. Bouillet P., Metcalf D., Huang D.C.S., Tarlinton D.M., Kay T.W.H., Köntgen F., Adams J.M., Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 286:1999;1735-1738.
167. Bouillet P., Purton J.F., Godfrey D.I., Zhang L.-C., Coultas L., Puthalakath H., Pellegrini M., Cory S., Adams J.M., Strasser A. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 415:2002;922-926. Genetic ablation of the proapoptotic Bcl-2 family member Bim leads to defective negative selection of thymocytes, indicating the negative selection may occur via the action of Bim.
168. -/- T cells show impaired deletion to superantigens in vivo. They provide evidence that suggests a balance of Bcl-2 and Bim regulates apoptosis.